5-3 Final Project Milestone Two: Disease Pathology, Management, and Pharmacological Impact Summary

BIO 212 Milestone Two Guidelines and Rubric Disease Pathology, Management, and Pharmacological Impact Summary

Submit a disease pathology, management, and pharmacological impact summary based on your two chosen diseases. Your summary should explain the characteristics of the infectious agent causing the diseases, lab tests used for identification, and the mechanism in which the diseases interfere with normal pathophysiology. You will also describe current treatment trends used in the management of the diseases, identify which class of drug has the most evidence to support its use in the pharmacological treatments, illustrate the mechanism the pharmacological treatments use to combat infection, and explain how preventative and protective measures can be enhanced for each disease to reduce infection and disease transmission. Specifically, the following critical elements must be addressed:

I. Disease Pathology

A. Describe the characteristics of infectious agent causing diseases, including structure and toxicities. B. Describe lab tests used for identification of the chosen organisms. C. Explain the mechanism in which the diseases interfere with normal pathophysiology. Be sure to describe how the infectious agent enters the cell

and establishes infection in the nucleus. D. Identify signs and symptoms of disease presentation for clinical diagnostics in support of therapeutic interventions for both diseases.

II. Disease Management and Pharmacological Impact A. Describe pharmacological and nonpharmacological current treatment trends used to control microbial growth for each disease, and explain how

such treatments promote patient care. B. Determine which class of drug has the most evidence to support its use in the pharmacological treatment of each disease, providing rationale. C. Illustrate the mechanism and principles these pharmacological treatments use to combat infection. D. Explain how preventative and protective measures can be enhanced for each disease to effectively reduce infection rates and disease

transmission, supported by research.

Rubric What to Submit: Milestone Two should be 1 to 2 pages in length. Write one page for each disease. Use double-spacing, 12-point Times New Roman font, and one-inch margins. All citations should follow proper APA guidelines. AI Usage If you use gen AI tools to support your work on this assignment, be sure to follow these AI usage guidelines. You must acknowledge your use of these tools in your work. Guidelines on how to cite AI tools can be found in this Shapiro Library guide.

Critical Elements Meets Expectations (100%) Partially Meets Expectations (75%) Does Not Meet Expectations (0%) Value

Disease Pathology: Characteristics

Describes the characteristics of infectious agent causing the diseases, including structure and toxicities

Describes the characteristics of infectious agent causing the diseases, including structure and toxicities, but description is cursory or illogical or contains inaccuracies, or does not address both diseases

Does not describe the characteristics of infectious agent causing the diseases, including structure and toxicities

11.25

Disease Pathology: Lab Tests Describes lab tests used for identification of the chosen organisms

Describes lab tests used for identification of the chosen organisms, but lab tests described are not appropriate for identification, or does not address both diseases

Does not describe lab tests used for the identification of the chosen organisms

11.25

Disease Pathology: Mechanism

Explains the mechanism in which the diseases interfere with normal pathophysiology, describing how the infectious agent enters the cell and establishes infection in the nucleus

Explains the mechanism in which the diseases interfere with normal pathophysiology, but explanation is illogical, contains inaccuracies, lacks detail, or does not address both diseases

Does not explain the mechanism in which the diseases interfere with normal pathophysiology

11.25

Disease Pathology: Signs and Symptoms

Identifies signs and symptoms of disease presentation for clinical diagnostics in support of therapeutic interventions for both diseases

Identifies signs and symptoms of disease presentation for clinical diagnostics in support of therapeutic interventions, but identification is illogical or contains inaccuracies, fails to justify therapeutic interventions, or does not address both diseases

Does not identify signs and symptoms of disease presentation for clinical diagnostics in support of therapeutic interventions

11.25

Disease Management and Pharmacological Impact:

Treatment Trends

Describes current pharmacological and nonpharmacological treatment trends used to control microbial growth for each disease, and explains how such treatments are used to promote patient care

Describes current pharmacological and nonpharmacological treatment trends used to control microbial growth, but description is cursory, illogical, or fails to address how treatments promote patient care, or description does not address both diseases

Does not describe current pharmacological and nonpharmacological treatment trends used to control microbial growth for each disease

11.25

Disease Management and Pharmacological Impact:

Class of Drug

Determines which class of drug has the most evidence to support its use in the pharmacological treatment of each disease, providing rationale

Determines which class of drug supports its use in the pharmacological treatment of each disease, but does not provide sufficient rationale or does not address both diseases

Does not determine which class of drug has the most evidence to support its use in the pharmacological treatment

11.25

Disease Management and Pharmacological Impact:

Mechanism and Principles

Illustrates the mechanism and principles these pharmacological treatments use to combat infection

Illustrates the mechanism and principles these pharmacological treatments use to combat infection, but illustration is unclear, lacks detail, or does not address both diseases

Does not illustrate the mechanism and principles these pharmacological treatments use to combat infection

11.25

Disease Management and Pharmacological Impact:

Preventative and Protective Measures Enhanced

Explains how preventative and protective measures can be enhanced for each disease to effectively reduce infection rates and disease transmission and supports explanation with research

Explains how preventative and protective measures can be enhanced for each disease to effectively reduce infection rates and disease transmission, but explanation is unclear or illogical, is not supported by research, or does not address both diseases

Does not explain how preventative and protective measures can be enhanced for each disease to effectively reduce infection rates and disease transmission

11.25

Clear Communication Consistently and effectively communicates in an organized way to a specific audience

Shows progress toward meeting expectations, but communication is inconsistent or ineffective in a way that negatively impacts understanding

Shows no evidence of consistent, effective, or organized communication

10

Total 100%